| December 20, 2011 | Cerenis to present at JP Morgan Healthcare conference |
| November 22, 2011 | Cerenis Appoints John F. Paolini as Chief Medical Officer |
| November 22, 2011 | The Board of Cerenis appoints Dr. Richard C. Pasternak as Non Executive Director |
| March 15, 2011 | Cerenis Initiates Phase 2 Study of Lead Product Candidate, CER-001, in Patients with Acute Coronary Syndrome |
| October 21, 2010 | Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing |
| July 26, 2010 | Cerenis Therapeutics raises EUR 40 million in series C financing |
| July 26, 2010 | Cerenis Therapeutics and Novasep awarded EUR 10.7 million funding from the French Government for the development CER-001, an HDL mimetic |
| July 21, 2010 | Cerenis to Present Clinical Proof-of-Concept Results for its CER-627 program (niacin/aspirin combinations) at the European Atherosclerosis Society Congress June 20-23 |
| May 18, 2010 | Cerenis Reports Positive Results for Phase 1 Study of CER-001, An HDL Mimetic, for the Treatment of Cardiovascular Disease |
| September 2, 2009 | Cerenis Therapeutics Adds Three Pharmaceutical Industry Veterans to its Clinical, Regulatory Affairs and Business Development Teams |
| February 10, 2009 | Cerenis Therapeutics Receives EUR 2.5 Million Investment from French Government through OSEO |
| February 3, 2009 | Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis |
| May 15, 2008 | Cerenis Therapeutics Completes Phase I Clinical Trial |
| January 1, 2008 | Robert A. Scott, M.D., Appointed Chief Medical Officer of Cerenis Therapeutics |
| July 18, 2007 | Cerenis Therapeutics Announces the Addition of Three Pharmaceutical Industry Veterans to its Management Team |
| March 21, 2007 | Cerenis Therapeutics Announces Formation of Scientific Advisory Board and Expansion of Board of Directors |
| November 13, 2006 | Cerenis Therapeutics Closes EUR 42.1million Financing |
| April 11, 2006 | Cerenis Therapeutics Receives the "French Life Sciences Award" from AFII |
| August 30, 2005 | Cerenis Therapeutics Announces License Agreement with Nippon Chemiphar to Develop New Therapies Based on PPAR Delta Agonists |
| August 22, 2005 | Cerenis Therapeutics Completes EUR 25 Million ($30.5 Million) Series A Financing to Progress HDL-Related Drugs for Cardiovascular Diseases |
